ALS: Understanding Motor Neuron Loss

Amyotrophic lateral sclerosis represents one of the most formidable and devastating neurodegenerative challenges in contemporary medicine, systematically dismantling the neural pathways that govern voluntary muscular movement. As a progressive disorder characterized by the concurrent destruction of both upper and lower motor neurons, it strips individuals of motor autonomy while frequently sparing sensory and autonomic modalities. Understanding its multifaceted pathophysiology, clinical manifestations, and emerging therapeutic avenues is essential for clinicians, neuroscientists, and interdisciplinary caregivers dedicated to mitigating its relentless progression.

Amyotrophic Lateral Sclerosis (ALS)

1. Concise Definition

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disorder marked by the selective degeneration of upper motor neurons in the cerebral cortex and lower motor neurons in the brainstem and spinal cord. Clinically, this catastrophic neuronal loss produces progressive muscle weakness, muscular atrophy, fasciculations, spasticity, and eventual paralysis, culminating typically in respiratory failure within two to five years from symptomatic onset.

Beyond its traditional classification as a purely neuromuscular pathology, contemporary medicine recognizes ALS as a clinically and biologically heterogeneous syndrome. The condition exists along a pathological continuum with frontotemporal dementia (FTD), sharing neuropathological hallmarks such as intracellular protein aggregates. While somatic motor function is predominantly attacked, sensory networks, oculomotor control, and visceral autonomic functions are characteristically preserved throughout the greater course of the illness.

The disease presents primarily in two forms: sporadic ALS (sALS), which constitutes approximately 90% to 95% of all identified presentations without an overt familial lineage, and familial ALS (fALS), which accounts for the remaining 5% to 10% and follows predominantly autosomal dominant inheritance patterns linked to distinct genetic mutations.

2. Etymology & Linguistic Origin

The nomenclature of amyotrophic lateral sclerosis derives directly from Classical Greek roots combined with pathological observation. The term was coined in the late nineteenth century to describe both the macroscopic muscular consequences and the microscopic spinal cord pathology observed on autopsy.

The word amyotrophic is composed of the Greek negative prefix a- (without), mys (muscle, stem myo-), and trophe (nourishment or sustenance). Taken together, “amyotrophy” literally translates to “a lack of muscle nourishment,” reflecting the profound denervation-induced wasting and atrophy of skeletal muscles that occurs when lower motor neurons perish. The term lateral stems from the Latin lateralis (pertaining to the side), designating the lateral columns or funiculi of the spinal cord where the corticospinal axons descend. Finally, sclerosis originates from the Greek sklerosis (hardening), describing the firm, fibrillary gliosis and scarring that replaces degenerated axonal pathways in post-mortem spinal specimens.

3. Pronunciation & Grammatical Form

The term is phonetically pronounced as /ˌeɪ.maɪ.əˈtrɒf.ɪk ˈlæt.ər.əl sklɪəˈroʊ.sɪs/ in American English and /ˌeɪ.maɪ.əʊˈtrɒf.ɪk ˈlæt.ər.əl sklɪəˈrəʊ.sɪs/ in British English. Colloquially and clinically, it is almost universally referred to by its acronym, ALS (pronounced /ˌeɪ.el.ˈes/).

Grammatically, “amyotrophic lateral sclerosis” functions as an uncountable, singular proper noun phrase. The adjectival form is “amyotrophic” or “ALS-related” (e.g., “amyotrophic pathology,” “ALS-associated functional decline”). In clinical discourse, individuals living with the diagnosis are accurately described as “patients with ALS” or “individuals diagnosed with ALS” rather than passive constructions, preserving person-first nomenclature.

4. Detailed Conceptual Explanation

To conceptualize the pathophysiology of ALS, one must examine the voluntary motor circuitry of the human central nervous system. Voluntary movement depends upon a two-tier neuronal hierarchy: the upper motor neurons (UMNs), whose cell bodies (Betz cells) reside within layer V of the primary motor cortex, and the lower motor neurons (LMNs), situated within the motor nuclei of the brainstem and the anterior horns of the spinal cord. In healthy physiology, upper motor neurons propagate action potentials down the corticospinal and corticobulbar tracts, synapsing directly or through interneurons onto lower motor neurons, which in turn project through peripheral nerves to innervate neuromuscular junctions across target skeletal musculature.

In ALS, a catastrophic and concurrent breakdown occurs across both compartments. The loss of upper motor neurons eliminates inhibitory descending control, manifesting clinically as spasticity, pathological hyperreflexia, pseudobulbar affect, and the emergence of primitive reflexes such as the Babinski sign. Simultaneously, the degeneration of lower motor neurons severs the direct physical connection between the nervous system and the periphery. This causes progressive flaccid paralysis, muscular fasciculations (spontaneous involuntary discharges of dying motor units), profound neurogenic atrophy, and muscle cramps.

At the microscopic and molecular level, the destruction of these cells is not governed by a singular, isolated event, but by a convergent cascade of cellular dysfunctions. Key mechanisms include:

• TDP-43 Proteinopathy: Over 97% of all ALS cases exhibit abnormal cytoplasmic aggregation, ubiquitination, phosphorylation, and nuclear depletion of the TDP-43 (TAR DNA-binding protein 43), disrupting cellular RNA metabolism.
• Glutamate Excitotoxicity: Impaired clearance of the excitatory neurotransmitter glutamate from the synaptic cleft, predominantly mediated by the downregulation of astrocytic excitatory amino acid transporter 2 (EAAT2), allows excessive calcium influx through postsynaptic NMDA and AMPA receptors, triggering enzymatic autodigestion and apoptosis.
• Mitochondrial Dysfunction and Oxidative Stress: Structural anomalies in neuronal mitochondria disrupt oxidative phosphorylation, generate lethal quantities of reactive oxygen species (ROS), and impair cellular bioenergetics.
• Defective Nucleocytoplasmic Transport: Structural defects within the nuclear pore complex obstruct the bidirectional movement of essential RNAs and proteins between the nucleus and the cytoplasm.
• Neuroinflammation and Non-Cell-Autonomous Death: Microglia and astrocytes transition from supportive neuroprotective roles into neurotoxic phenotypes, releasing pro-inflammatory cytokines that accelerate motor neuron demise.

The spatial and temporal progression of ALS typically reflects contiguous anatomical spreading. Beginning focally in a specific spinal segment or the bulbar territory, the degenerative process spreads to adjacent motor neuron pools through what many researchers hypothesize to be a prion-like propagation of misfolded pathological proteins across synaptic networks.

5. Historical Development

The definitive clinical and pathological characterization of ALS is historically credited to the renowned nineteenth-century French neurologist Jean-Martin Charcot. Between 1865 and 1874, working at the Salpêtrière Hospital in Paris, Charcot conducted meticulous clinicopathological correlations. He systematically separated this unique condition from other forms of muscular paralysis, such as progressive muscular atrophy (described earlier by François-Amilcar Aran and Guillaume Duchenne) and multiple sclerosis. Charcot accurately identified that the concurrent presence of both muscle wasting (amyotrophy) and spastic contractures (lateral sclerosis) constituted a distinct nosological entity, officially publishing his treatise on sclérose latérale amyotrophique in 1874. In much of continental Europe and Latin America, the condition continues to be honored under the eponym Charcot’s disease.

In the Anglophone world, particularly in North America, ALS entered the broader public consciousness in 1939 when Lou Gehrig, the legendary first baseman for the New York Yankees, was diagnosed with the condition at the age of 36. His high-profile retirement and subsequent death in 1941 cemented the term “Lou Gehrig’s disease” into popular American vocabulary. In the United Kingdom and Australasia, the condition is commonly subsumed under the broader umbrella term Motor Neurone Disease (MND), of which ALS is the most prevalent variant.

The modern molecular era of ALS research commenced in 1993, when an international consortium led by Robert Brown discovered mutations in the SOD1 (superoxide dismutase 1) gene on chromosome 21 in families with inherited ALS. This ground-breaking discovery established that genetic aberrations alone could induce the disease phenotype. The field was revolutionized again in 2006 when Manuela Neumann and Virginia Lee discovered that TDP-43 was the primary constituent of ubiquitinated cytoplasmic inclusions in both sporadic ALS and frontotemporal lobar degeneration. In 2011, the identification of the C9orf72 hexanucleotide repeat expansion solidified the biological unity between ALS and frontotemporal dementia, reshaping the modern genetic and pathophysiological paradigm of the disease.

6. Theoretical Foundations

The academic understanding of ALS has evolved through several overarching paradigms, progressing from mechanical cellular damage theories to intricate non-cell-autonomous network hypotheses.

The earliest functional model was the Purely Neurocentric Hypothesis, which posited that ALS was driven exclusively by cell-intrinsic vulnerabilities within large, heavily myelinated motor neurons. Motor neurons are uniquely vulnerable due to their enormous physical size, long metabolic transport distances (axons exceeding one meter in length), elevated bioenergetic demands, and poor intrinsic cytosolic calcium buffering capacity. Under this paradigm, metabolic collapse within the motor neuron alone accounted for the degenerative cascade.

In contrast, the Non-Cell-Autonomous Disease Model gained ascendancy in the early 2000s, supported by transgenic rodent models. This framework demonstrates that while the initial pathological insult may originate within the motor neuron, surrounding non-neuronal glial cells dictate the tempo of neurodegeneration. Infiltrating reactive astrocytes, hyper-activated microglia, and dysfunctional oligodendrocytes fail to provide critical trophic support and actively secrete neurotoxic factors, converting the local microenvironment into an inflammatory zone that accelerates motor neuron apoptosis.

Most recently, the Multistep Oligogenic and Environmental Liability Model frames ALS through an epidemiological and systemic lens. Analogous to the multi-hit model of oncogenesis, this theory posits that ALS results from a sequence of approximately four to six discrete pathogenic steps. These steps involve a composite of baseline polygenic susceptibility, epigenetic modifications, lifetime biological aging, and toxic environmental exposures (such as heavy metals, pesticides, or physical trauma), which collectively overwhelm cellular proteostasis and repair networks.

7. Key Components, Types & Dimensions

ALS manifests with substantial heterogeneity, classified primarily by site of clinical onset and underlying genetic etiology:

• Spinal (Limb) Onset ALS: The most common presentation, occurring in approximately 65% to 70% of individuals. Symptoms initiate distally in the limbs, such as unilateral foot drop, asymmetrical hand weakness, loss of fine motor dexterity (e.g., difficulty buttoning shirts or turning keys), and localized muscle wasting accompanied by fasciculations.
• Bulbar Onset ALS: Accounting for approximately 25% to 30% of cases, this presentation is characterized by early degeneration of motor nuclei in the medulla oblongata. It manifests with progressive dysarthria (slurred or nasal speech), dysphagia (difficulty swallowing solids and liquids), tongue fasciculations and atrophy, chewing difficulty, and excessive drooling (sialorrhea). Bulbar onset typically exhibits a faster clinical progression.
• Respiratory Onset ALS: A rare variant (constituting 1% to 3% of presentations) characterized by primary failure of the diaphragm and intercostal muscles before substantial limb or bulbar wasting is apparent. It presents with progressive orthopnea, morning headaches, dyspnea on exertion, and early hypercapnic respiratory insufficiency.
• Sporadic ALS (sALS): Comprising roughly 90% of cases, arising in individuals with no prior family history of motor neuron disease, driven by a complex interplay of subtle genetic risk variants and environmental triggers.
• Familial ALS (fALS): Comprising 5% to 10% of cases, characterized by an autosomal dominant (or rarely recessive/X-linked) inheritance pattern. Major causative genes include:
  • C9orf72: Hexanucleotide GGGGCC repeat expansions, accounting for 30% to 40% of fALS and approximately 5% to 10% of sALS.
  • SOD1: Point mutations driving toxic gain-of-function enzymatic misfolding, accounting for 12% to 20% of fALS.
  • TARDBP: Mutations in the gene encoding TDP-43, found in 4% to 5% of fALS cases.
  • FUS: Mutations affecting the fused in sarcoma RNA-binding protein, often associated with aggressive, early-onset disease phenotypes.
• Cognitive and Behavioral Dimensions (ALS-FTD): Up to 50% of ALS patients display measurable frontotemporal cognitive impairment, particularly executive dysfunction, apathy, and language deficits. Between 10% and 15% meet formal diagnostic criteria for comorbid behavioral variant Frontotemporal Dementia (bvFTD).

8. Examples & Illustrative Cases

Case 1: Typical Spinal Onset. A 58-year-old carpenter presents with an eight-month history of painless, progressive weakness in his dominant right hand. Initially, he noted difficulty holding nails and turning doorknobs. Over three months, the weakness spread proximally into the forearm, accompanied by localized twitching under the skin. Neurological examination reveals marked atrophy of the right first dorsal interosseous and thenar muscles, accompanied by visible fasciculations. However, deep tendon reflexes in the same arm are markedly hyperactive (3+), and an unsustained clonus is noted at the right ankle. This direct juxtaposition of lower motor neuron signs (atrophy, fasciculations) and upper motor neuron signs (hyperreflexia, clonus) in the same anatomical segment raises strong clinical suspicion of ALS.

Case 2: Bulbar Onset with Pseudobulbar Affect. A 66-year-old woman presents with progressive slurring of speech over five months, often mistaken by peers for intoxication. Within weeks, she develops coughing and choking spells when drinking thin liquids. Concurrently, she experiences distressing, uncontrollable episodes of crying or laughing that do not align with her underlying emotional state (pseudobulbar affect). Physical examination demonstrates a furrowed, atrophic tongue exhibiting continuous fasciculations, bilateral spasticity of the jaw jerk reflex, and a hyperactive gag reflex. The preservation of brisk reflexes in the context of profoundly wasted, denervated bulbar musculature highlights the classic coexistence of corticobulbar and lower cranial nerve nuclear degradation.

9. Measurement & Assessment

The diagnosis of ALS is fundamentally clinical, reliant on expert neurological synthesis supported by neurophysiological and neuroimaging modalities to rule out competing pathologies. Because no single definitive laboratory test exists, international consensus criteria have been developed to standardize diagnostic certainty:

• The Revised El Escorial Criteria: Categorizes diagnostic probability into “Definite,” “Probable,” “Probable with Laboratory Support,” and “Possible” ALS based on the clinical presence of upper and lower motor neuron signs across three or four anatomical regions: bulbar, cervical, thoracic, and lumbosacral.
• The Awaji Criteria: An evolution of the El Escorial framework that elevates neurophysiological findings from electromyography (EMG) to equal diagnostic status with clinical physical signs. Under Awaji recommendations, electromyographic evidence of acute denervation (fibrillation potentials, positive sharp waves) alongside chronic denervation-reinnervation changes (large, polyphasic motor unit potentials) confirms lower motor neuron dysfunction.
• The Gold Coast Criteria: A streamlined modernization designed to improve sensitivity and simplify clinical trial enrollment. It requires the presence of upper and lower motor neuron dysfunction in at least one body region, or lower motor neuron dysfunction in at least two body regions, alongside disease progression and the exclusion of mimicking pathologies.
• The Revised ALS Functional Rating Scale (ALSFRS-R): The primary clinical and research measurement tool used to monitor disease trajectory. It evaluates twelve functional parameters across four domains: speech, salivation, and swallowing (bulbar); handwriting, cutting food, and dressing/hygiene (fine motor); walking and climbing stairs (gross motor); and dyspnea, orthopnea, and respiratory insufficiency (respiratory). Scored from 0 to 48, lower scores indicate progressive functional disability.
• Fluid Biomarkers: Measurement of Neurofilament Light Chain (NfL) and phosphorylated Neurofilament Heavy (pNfH) in serum and cerebrospinal fluid. Elevated neurofilament levels reflect structural axonal destruction, serving as potent prognostic indicators of disease aggressiveness and therapeutic response markers in clinical trials.

10. Applications & Practical Significance

Management of ALS necessitates a specialized, multidisciplinary clinic model involving neurologists, pulmonologists, physical therapists, occupational therapists, speech-language pathologists, dietitians, and palliative specialists. This multidisciplinary framework is clinically proven to extend life expectancy and improve patient-reported quality of life more effectively than any single pharmacological intervention.

Pharmacological therapies approved to alter disease progression include:

• Riluzole: An anti-excitotoxic agent that inhibits voltage-gated sodium channels and dampens glutamate release. It offers an established survival extension of two to three months, often prolonging earlier disease stages.
• Edaravone: A free radical scavenger and antioxidant administered intravenously or orally, designed to mitigate oxidative damage to motor neurons and slow functional decline as measured by the ALSFRS-R in selected early-stage patient cohorts.
• Tofersen: An antisense oligonucleotide targeting mutations in the SOD1 gene. Administered via intrathecal injection, it reduces mutant SOD1 protein synthesis and significantly lowers neurofilament levels, marking a major milestone for precision genetic medicine in neurodegeneration.

Supportive interventions remain central to ALS clinical practice. Non-invasive ventilation (NIV), typically initiated using bilevel positive airway pressure (BiPAP), provides crucial support as diaphragmatic weakness develops, preserving quality of life and extending survival by months. Nutritional management via percutaneous endoscopic gastrostomy (PEG) tubes preserves caloric intake and hydration while circumventing the choking hazards linked to severe dysphagia. Assistive communication devices, ranging from eye-tracking computer systems to synthetic speech generators, preserve cognitive autonomy and relational connection even amidst profound somatic paralysis.

11. Research & Empirical Evidence

Over the past three decades, empirical research into ALS has accelerated through global multicenter consortia, genomic sequencing initiatives, and human-induced pluripotent stem cell (iPSC) modeling.

Landmark studies led by the international Project MinE consortium have sequenced thousands of whole genomes from ALS patients and control subjects, pinpointing rare genetic variants and polygenic risk architectures. These inquiries have confirmed that sporadic ALS frequently arises from oligogenic inheritance patterns, where the convergence of several modest-effect genetic variants lowers the threshold for neuronal breakdown.

The role of pathological liquid-liquid phase separation has emerged as a central theme in laboratory research. Investigations led by researchers such as J. Paul Taylor and colleagues showed that RNA-binding proteins like TDP-43 and FUS normally form dynamic, reversible ribonucleoprotein complexes known as stress granules. In ALS, pathological mutations or chronic environmental stress cause these functional membraneless organelles to transition into irreversible, insoluble, neurotoxic fibrillar aggregates.

Furthermore, therapeutic pipelines are evaluating diverse modalities including gene therapy vectors, monoclonal antibodies designed to neutralize misfolded extracellular proteins, immunomodulatory therapies designed to expand anti-inflammatory regulatory T cells (Tregs), and modulators of the integrated stress response. The clinical validation of neurofilament light chain as an objective, pharmacodynamic biomarker has transformed trial designs, allowing researchers to evaluate therapeutic target engagement within months rather than years.

12. Cultural & Cross-Cultural Considerations

The epidemiological landscape and public perception of ALS display distinct cross-cultural variations. Globally, the incidence of ALS is relatively uniform across Western Europe and North America, ranging from 1.5 to 2.5 cases per 100,000 person-years. However, historically, dramatic geographic clusters were identified in the Western Pacific, specifically among the Chamorro people of Guam, the Kii Peninsula of Japan, and West New Guinea. This local presentation—termed the Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex (ALS-PDC)—exhibited incidence rates up to one hundred times higher than global baselines. Extensive investigations have examined dietary exposure to neurotoxic non-protein amino acids like cycad flour-derived BMAA (beta-methylamino-L-alanine), alongside unique founder genetic traits, though modern incidence rates in these regions have steadily fallen toward global baselines as lifestyles transitioned.

Cultural attitudes deeply influence clinical decision-making regarding invasive end-of-life interventions. In nations such as the United States, Canada, and parts of Western Europe, patient autonomy and advance directives frequently lead individuals to decline invasive mechanical ventilation via tracheostomy, opting instead for palliative withdrawal and hospice care upon the failure of non-invasive modalities. Conversely, in countries such as Japan, cultural paradigms surrounding familial duty and filial care often result in higher rates of tracheostomy and long-term invasive mechanical ventilation, profoundly altering the duration and sociomedical trajectory of the disease.

13. Criticisms, Debates & Limitations

A prominent debate in modern neurology centers on whether ALS should be classified as a single coherent disease or an umbrella syndrome. Many researchers argue that “ALS” represents a stereotypic final common pathway of motor system collapse triggered by fundamentally divergent upstream biochemical defects. Consequently, therapeutic trials designed around monolithic cohorts frequently fail because a drug targeting a specific biological mechanism (such as glutamate clearance) may prove inert in individuals whose disease is driven by primary proteasomal clearance failure, retrotransposon reactivation, or mitochondrial respiratory collapse.

Another longstanding source of debate concerns the translational disconnect between preclinical animal models and human clinical realities. For nearly three decades, the transgenic SOD1 mouse model served as the primary experimental platform for therapeutic discovery. Over fifty candidate agents demonstrated preclinical efficacy in these rodent cohorts, yet virtually all failed to demonstrate meaningful survival benefits in human clinical trials. Critics emphasize that SOD1 models represent an atypical, non-TDP-43-driven subform of the disease, and that animal testing regimens historically suffered from poor statistical power and flawed blinding protocols.

Additionally, ethical complexities surround modern predictive genetic testing. With the arrival of targeted gene therapies like tofersen, identifying asymptomatic carriers of pathogenic C9orf72 or SOD1 mutations has gained therapeutic relevance. However, because these mutations display variable and incomplete penetrance, predicting the precise age of onset or specific phenotype remains impossible, imposing substantial psychological stress on carriers and complicating family planning dynamics.

14. Related Terms & Distinctions

ALS exists within a spectrum of motor and neurodegenerative conditions. Distinguishing it from related disorders is vital for diagnostic and therapeutic clarity:

• Primary Lateral Sclerosis (PLS): A motor neuron disorder characterized solely by the progressive loss of upper motor neurons. In contrast to ALS, PLS displays no clinical or electromyographic evidence of lower motor neuron degeneration during its initial years, features a much slower rate of progression, and carries a substantially longer life expectancy.
• Progressive Muscular Atrophy (PMA): A presentation restricted to lower motor neuron degeneration, lacking overt clinical signs of corticospinal tract involvement (spasticity, brisk reflexes). Debate continues over whether PMA is a distinct entity or an exclusively lower-motor phenotypic variant of ALS.
• Progressive Bulbar Palsy (PBP): A clinical manifestation characterized by initial involvement limited to bulbar territories, presenting with speech and swallowing failure. While initially localized, PBP typically spreads to spinal regions, evolving into typical ALS over time.
• Spinal Muscular Atrophy (SMA): A hereditary childhood- or young-adult-onset lower motor neuron disease caused by biallelic mutations or deletions in the SMN1 gene on chromosome 5q. Unlike ALS, classic SMA is strictly lower motor neuron in nature and is non-cell-autonomously driven by ubiquitous SMN protein depletion.
• Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy): An X-linked recessive disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor gene. Clinically resembling motor neuron disease, it is distinguished from ALS by the presence of prominent perioral fasciculations, sensory neuropathy, and systemic endocrine manifestations such as gynecomastia.
• Frontotemporal Dementia (FTD): A neurodegenerative syndrome affecting the frontal and temporal lobes. While classic FTD manifests primarily as changes in personality, social behavior, or language processing without obligatory motor impairment, its molecular overlap with ALS (particularly TDP-43 aggregation) links both conditions along a single neurodegenerative spectrum.

15. Key Takeaways

Amyotrophic lateral sclerosis is an aggressive neurodegenerative syndrome defined by the combined loss of both upper and lower motor neurons across cortical, bulbar, and spinal motor pathways. Driven by a multifaceted convergence of genetic variations, TDP-43 proteostasis failure, glutamate excitotoxicity, and non-cell-autonomous glial inflammation, the disease leads inexorably to progressive weakness and respiratory failure. While current pharmacological tools like riluzole, edaravone, and gene-targeted antisense oligonucleotides provide meaningful, incremental clinical advantages, the cornerstone of care remains aggressive, proactive multidisciplinary symptom management, early respiratory assistance, and comprehensive supportive care.

The management of amyotrophic lateral sclerosis represents a true convergence of rapid molecular discoveries and patient-centered, multidisciplinary clinical support. As targeted therapies emerge to address individual genetic drivers and cellular misfolding pathways, ALS is steadily transitioning from an intractable mystery toward a disorder with defined molecular targets and expanding therapeutic potential.

References

• Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. New England Journal of Medicine, 377(2), 162–172. https://doi.org/10.1056/NEJMra1603471
• Charcot, J. M. (1874). De la sclérose latérale amyotrophique. Progrès Médical, 2, 325–327.
• Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017). Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 3(1), 17071. https://doi.org/10.1038/nrdp.2017.71
• Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., McCluskey, L. F., Miller, B. L., Masliah, E., Mackenzie, I. R., Feldman, H., Feiden, W., Kretzschmar, H. A., Trojanowski, J. Q., & Lee, V. M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130–133. https://doi.org/10.1126/science.1134108
• Taylor, J. P., Brown, R. H., & Cleveland, D. W. (2016). Decoding ALS: From genes to mechanism. Nature, 539(7628), 197–206. https://doi.org/10.1038/nature20413